2016 Review and Outlook: What Got You Here May Not Get You There

The biopharma industry begins 2016 with more sober capital markets, the emergence of a new class of innovative therapies, increased competition and ongoing evidence that the industry's underlying economics are unstable in the long term. In our annual Review and Outlook, we examine how these forces will be affecting the senior talent market. Investor scrutiny of boards and CEOs will increase, there will be greater focus on shareholder management and pricing will be a collective challenge for the entire C-suite.